Ticker
OTLK
1 report from NewsMeter on OTLK, newest first.
OTLK's LYTENAVA wins FDA approval as first ophthalmic bevacizumab for wet AMD, targeting $8.5 billion retina market
Markets
Jul 25, 2026
← All tickers